Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lung mucosal and systemic responses at single-cell resolution in an aerosolized Mycobacterium bovis BCG human challenge model.

Cell reports. Medicine·2026
Same author

Domain arrangement-driven immunogenicity of a computationally designed mRNA vaccine targeting PPE68, IrtA, and PE9 of Mycobacterium tuberculosis.

Scientific reports·2026
Same author

Enhancing tuberculosis vaccine efficacy with a heterologous mRNA-ChAdOx1 prime-pull strategy targeting lung-resident memory T cells.

Frontiers in immunology·2026
Same author

The influence of murine cytomegalovirus infection on susceptibility to mycobacterial infection.

iScience·2026
Same author

Delayed Hypersensitivity to Intralesional Meglumine Antimoniate for Cutaneous Leishmaniasis.

The American journal of tropical medicine and hygiene·2025
Same author

Leishmaniasis in the United Kingdom: Experience of a national multidisciplinary team meeting in a non-endemic setting.

Travel medicine and infectious disease·2025

Related Experiment Video

Updated: May 30, 2026

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis
06:26

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Published on: July 28, 2023

Tuberculosis vaccines: progress and challenges.

Anna M Checkley1, Helen McShane

  • 1Jenner Institute, Nuffield Department of Medicine, Oxford University, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK.

Trends in Pharmacological Sciences
|August 2, 2011
PubMed
Summary

Developing an effective tuberculosis (TB) vaccine is crucial for pandemic control. Current research focuses on improving the bacille Calmette-Guerin (BCG) vaccine and exploring novel candidates, facing challenges in clinical trials.

More Related Videos

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System
10:11

Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System

Published on: January 31, 2018

Related Experiment Videos

Last Updated: May 30, 2026

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis
06:26

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Published on: July 28, 2023

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System
10:11

Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System

Published on: January 31, 2018

Area of Science:

  • Vaccinology
  • Infectious Diseases
  • Immunology

Background:

  • Tuberculosis (TB) remains a global health challenge, necessitating effective vaccination strategies.
  • Significant investment has accelerated the development of promising TB vaccines currently in clinical trials.
  • Existing strategies involve enhancing the bacille Calmette-Guerin (BCG) vaccine and developing booster vaccines.

Purpose of the Study:

  • To outline the current TB vaccination strategy.
  • To review key challenges in the development of novel TB vaccines.
  • To evaluate the progression of vaccine candidates from pre-clinical to clinical stages.

Main Methods:

  • Review of current TB vaccination strategies and ongoing research.
  • Evaluation of vaccine candidates in pre-clinical animal models.
  • Assessment of challenges in early-phase and large-scale efficacy clinical trials.

Main Results:

  • Several promising TB vaccine candidates are advancing through clinical trials.
  • A critical challenge in early trials is the absence of a defined correlate of immune protection.
  • Large efficacy trials face significant hurdles including cost, logistics, and site capacity.

Conclusions:

  • The development of an effective TB vaccine requires overcoming substantial challenges in clinical evaluation.
  • Defining correlates of protection is essential for efficient early-stage vaccine development.
  • Successful TB vaccine deployment hinges on addressing logistical and financial barriers in large-scale trials.